US Stocks Mixed; Home Depot Shares Gain After Q2 Results

U.S. equities traded mixed on Tuesday, with the Dow Jones gaining 0.50% and the S&P 500 up 0.07%, while the NASDAQ declined 0.43%. The Home Depot Inc. shares rose 4% despite second-quarter sales of $45.277 billion slightly missing Wall Street estimates and adjusted diluted EPS of $4.68 also falling short of consensus. Sector performance saw real estate shares jump 1.3% while communication services fell 1%. Notable individual stock movements included Viking Therapeutics dropping 41% after releasing disappointing Phase 2 trial data for its VK2735 pill, while Gaxos.ai surged 93% on a new platform launch. Economic data indicated U.S. housing starts increased 5.2% in July, though building permits declined.

Analysis

The U.S. market is exhibiting clear signs of divergence and a potential rotation, with the Dow Jones gaining 0.50% while the tech-centric NASDAQ fell 0.43%. This trend is mirrored in sector performance, where real estate shares advanced 1.3% against a 1% decline in communication services stocks. Corporate earnings provided a key focal point, particularly with The Home Depot (HD), which saw its shares rise 4% despite missing consensus estimates on both revenue ($45.277 billion vs. $45.356 billion estimate) and adjusted EPS ($4.68 vs. $4.71 estimate). This counterintuitive positive reaction suggests that either market expectations were sufficiently low or the stock is benefiting from a broader shift toward value. The biotech sector experienced a significant negative catalyst as Viking Therapeutics (VKTX) shares plummeted 41% following the release of disappointing Phase 2 trial data for its VK2735 pill. In contrast, speculative appetite remains strong in niche tech, evidenced by Gaxos.ai (GXAI) surging 93% on a new AI platform launch. The macroeconomic backdrop is mixed; U.S. housing starts rose 5.2% in July, but building permits, a forward-looking indicator, declined 2.8%, signaling potential future weakness in an otherwise strong real estate market.

Key Decisions for Investors

• Given the divergence between the Dow and NASDAQ, investors should assess their portfolio's balance between value and growth, as a sector rotation appears to be in progress.
• The 4% rise in Home Depot's stock despite an earnings miss warrants caution; its resilience may be tied more to the market's value rotation than to the company's fundamental performance.
• The 41% collapse of Viking Therapeutics highlights the binary risk inherent in clinical-stage biotechnology; any positions in event-driven biotech stocks should be appropriately sized and hedged against trial data outcomes.
• Extreme moves like the 93% surge in Gaxos.ai on a product announcement underscore the speculative nature of the AI theme, advising a cautious approach to similarly catalyzed micro-cap stocks.
• The conflicting housing data, with starts up 5.2% but permits down 2.8%, suggests monitoring forward-looking economic indicators for signs of a slowdown that could impact cyclical sectors.